for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akebia Therapeutics Inc

AKBA.OQ

Latest Trade

--

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

--

 - 

--

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Akebia Therapeutics Files Lawsuit Against CMS

Oct 15 (Reuters) - Akebia Therapeutics Inc <AKBA.O>::AKEBIA FILES LAWSUIT AGAINST CMS FOR 2018 ACTION RESCINDING MEDICARE PART D COVERAGE OF FDA-APPROVED AURYXIA® FOR ITS IRON DEFICIENCY ANEMIA INDICATION AND IMPOSING A PRIOR AUTHORIZATION REQUIREMENT FOR ITS HYPERPHOSPHATEMIA INDICATION.AKEBIA - LAWSUIT CHALLENGES A SEPT. 2018 DECISION BY CMS THAT RESCINDED MEDICARE PART D COVERAGE OF AURYXIA.AKEBIA THERAPEUTICS INC - IN COMPLAINT, CO ASKS COURT TO RESTORE COVERAGE OF AURYXIA FOR IDA INDICATION.AKEBIA THERAPEUTICS - LEGAL ACTION ALSO SEEKS TO REVERSE RELATED DECISION BY CMS THAT IMPOSED PRIOR AUTHORIZATION REQUIREMENT FOR AURYXIA.AKEBIA THERAPEUTICS INC - IN COMPLAINT, CO ASKS COURT TO REMOVE PRIOR AUTHORIZATION REQUIREMENT FOR HYPERPHOSPHATEMIA INDICATION.

Akebia Therapeutics Reports Q2 Loss Per Share $0.49

Aug 8 (Reuters) - Akebia Therapeutics Inc <AKBA.O>::AKEBIA THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND HOSTS CONFERENCE CALL TO DISCUSS RECENT BUSINESS HIGHLIGHTS.Q2 LOSS PER SHARE $0.49.Q2 REVENUE $100.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $91.1 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.AKEBIA THERAPEUTICS - EXPECT CASH RESOURCES TO FUND CURRENT OPERATING PLAN INTO Q3 2020.ENDED QUARTER WITH CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES OF $136.8 MILLION.

Akebia Therapeutics Announces Settlement Of Auryxia Patent Litigation With Par Pharmaceutical

Aug 5 (Reuters) - Akebia Therapeutics Inc <AKBA.O>::AKEBIA THERAPEUTICS® ANNOUNCES SETTLEMENT OF AURYXIA® PATENT LITIGATION WITH PAR PHARMACEUTICAL.AKEBIA THERAPEUTICS INC - KERYX BIOPHARMACEUTICALS AND ITS LICENSOR PANION & BF BIOTECH ENTERED INTO A SETTLEMENT AND LICENSE AGREEMENT.AKEBIA THERAPEUTICS INC - RESOLVES PATENT LITIGATION IN RESPONSE TO PAR'S ANDA SEEKING APPROVAL TO MARKET A GENERIC VERSION OF AURYXIA TABLETS.AKEBIA THERAPEUTICS - COS WILL GRANT PAR A LICENSE TO MARKET ITS GENERIC VERSION OF AURYXIA IN UNITED STATES BEGINNING ON MARCH 20, 2025 OR EARLIER.AKEBIA THERAPEUTICS INC - PARTIES WILL TERMINATE ALL ONGOING HATCH-WAXMAN LITIGATION BETWEEN KERYX AND PANION AND PAR.AKEBIA THERAPEUTICS INC - AGREEMENT IS CONFIDENTIAL AND SUBJECT TO REVIEW BY U.S. FEDERAL TRADE COMMISSION AND U.S. DEPARTMENT OF JUSTICE.

Akebia Therapeutics Reports Q1 Loss Per Share Of $0.62

May 9 (Reuters) - Akebia Therapeutics Inc <AKBA.O>::AKEBIA THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS; ANNOUNCES FULL ENROLLMENT OF PHASE 3 INNO2VATE STUDIES AND ANNOUNCES KEY EXECUTIVE APPOINTMENTS.Q1 LOSS PER SHARE $0.62.Q1 REVENUE $72.7 MILLION VERSUS REFINITIV IBES ESTIMATE OF $81 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.40 -- REFINITIV IBES DATA.NET PRODUCT REVENUE FOR AURYXIA INCREASES TO $23.1 MILLION FOR Q1'FY19, UP 12.1% FROM Q1'FY18.

Akebia Therapeutics Says Anticipates Delayed Filing Of Annual Report On Form 10-K

March 18 (Reuters) - Akebia Therapeutics Inc <AKBA.O>::AKEBIA THERAPEUTICS ANNOUNCES PRELIMINARY FULL-YEAR 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS.AKEBIA THERAPEUTICS INC - ENDED 2018 WITH CASH, CASH EQUIVALENTS AND AVAILABLE-FOR-SALE SECURITIES OF $321.6 MILLION.AKEBIA - SEES CASH RESOURCES, INCLUDING PREPAID QTRLY COMMITTED COST-SHARE COLLABORATION PARTNER FUNDING, TO FUND CURRENT OPERATING PLAN INTO Q3 2020.AKEBIA THERAPEUTICS - ANTICIPATES DELAYED FILING OF ANNUAL REPORT ON FORM 10-K FOR FISCAL YEAR ENDED DEC 31, 2018.AKEBIA THERAPEUTICS INC QTRLY PRELIMINARY COLLABORATION REVENUES $53.0 MILLION VERSUS $90.6 MILLION.AKEBIA THERAPEUTICS INC - NO REVENUE WAS RECOGNIZED UNDER MTPC COLLABORATION AGREEMENT IN Q4 OF 2018.AKEBIA THERAPEUTICS INC QTRLY PRELIMINARY PRE-TAX NET LOSS OF $88.4 MILLION VERSUS PRE-TAX NET INCOME OF $15.5 MILLION.

Akebia Therapeutics Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Vadadustat

March 12 (Reuters) - Akebia Therapeutics Inc <AKBA.O>::AKEBIA THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM TWO PIVOTAL PHASE 3 STUDIES OF VADADUSTAT IN JAPANESE PATIENTS WITH ANEMIA DUE TO CHRONIC KIDNEY DISEASE.EACH STUDY, ONE IN NON-DIALYSIS DEPENDENT SUBJECTS AND ONE IN HEMODIALYSIS-DEPENDENT SUBJECTS, MET ITS PRIMARY ENDPOINT.MITSUBISHI TANABE PHARMA CORPORATION EXPECTS TO SUBMIT A JAPANESE NEW DRUG APPLICATION IN 2019.

Nantahala Capital Management, Llc Reports 4.7 pct Stake In Akebia Therapeutics As Of Dec 12

Dec 21 (Reuters) - :NANTAHALA CAPITAL MANAGEMENT, LLC REPORTS 4.7 PERCENT STAKE IN AKEBIA THERAPEUTICS INC AS OF DEC 12, 2018 - SEC FILING.NANTAHALA CAPITAL MANAGEMENT, LLC - HAD PREVIOSULY REPORTED 9.8 PERCENT STAKE IN AKEBIA THERAPEUTICS INC AS OF SEPT 25, 2018.

ISS Recommends Keryx Biopharma Stockholders Vote For Proposed Merger With Akebia Therapeutics

Nov 29 (Reuters) - Akebia Therapeutics Inc <AKBA.O>::ISS RECOMMENDS THAT KERYX BIOPHARMACEUTICALS STOCKHOLDERS VOTE “FOR” THE PROPOSED MERGER WITH AKEBIA THERAPEUTICS.KERYX BIOPHARMACEUTICALS INC - LARGEST STOCKHOLDER, BAUPOST GROUP, LLC, HAS ENTERED INTO A VOTING AGREEMENT IN SUPPORT OF TRANSACTION.

Akebia Therapeutics And Keryx Biopharmaceuticals Announce Chairperson For Combined Company

Nov 15 (Reuters) - Akebia Therapeutics Inc <AKBA.O>::AKEBIA THERAPEUTICS AND KERYX BIOPHARMACEUTICALS ANNOUNCE CHAIRPERSON FOR COMBINED COMPANY.AKEBIA THERAPEUTICS INC - UPON COMPLETION OF MERGER, BOARD OF DIRECTORS WILL CONSIST OF TEN MEMBERS WITH ADAMS AS CHAIRPERSON..AKEBIA THERAPEUTICS INC - CURRENT AKEBIA BOARD MEMBER MAXINE GOWEN WILL CONTINUE TO SERVE AS A MEMBER OF BOARD.AKEBIA THERAPEUTICS - CO, KERYX SAYS ADRIAN ADAMS WILL SERVE AS CHAIRPERSON OF AKEBIA BOARD OF DIRECTORS, EFFECTIVE UPON PROPOSED MERGER COMPLETION.

Akebia Therapeutics Sends Letter To Shareholders

Akebia Therapeutics Inc <AKBA.O>::AKEBIA THERAPEUTICS SENDS LETTER TO SHAREHOLDERS.AKEBIA THERAPEUTICS - AKEBIA BOARD UNANIMOUSLY RECOMMENDS THAT AKEBIA SHAREHOLDERS VOTE "FOR" PROPOSALS RELATING TO PROPOSED MERGER WITH KERYX.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up